Health Care • Biotechnology: Pharmaceutical Preparations
$8.02 ▼ -0.18
(-2.19%)
MKT CAP: $3.07B • VOL: 4.94M
52W L $4 52W H $9
BHC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $10.27B | $9.63B | $8.76B |
| YoY Revenue Growth % | +6.7% | +9.9% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.81B | $1.55B | $963.0M |
| Operating Margin % | 17.7% | 16.1% | 11.0% |
| Net Income (GAAP) | $157.0M | -$46.0M | -$592.0M |
| EBITDA (Normalized) | $2.13B | $1.82B | $1.28B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.40B | $1.60B | $1.03B |
| Capital Expenditures (CapEx) | $397.0M | $337.0M | $394.1M |
| Free Cash Flow (FCF) | $1.00B | $1.26B | $637.9M |
| FCF Margin % | 9.8% | 13.1% | 7.3% |
| Return on Invested Capital (ROIC %) | 7.6% | 7.4% | 12.0% |
| Cash & Short-Term Equivalents | $1.31B | $1.18B | — |
| Total Debt (Short + Long Term) | $20.59B | $18.94B | $2.46B |
| Total Stockholders' Equity | -$554.0M | -$1.28B | $5.04B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BHC.